Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials with VP-102 CAMP-1 and CAMP-2. J of Skin. 2021;5(6):s92. doi:10.25251/skin.5.supp.92